LUNA

Clinical Trial

NCT06627179 Recruiting, Active

LUNA

A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Phase 2

Interventional

Disease

Disease type

Usher Syndrome

Orphan drug recognition

Yes

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

11/12/2024

Closing date

31/12/2027

Inclusion criteria :

Exclusion criteria :

Funding

Industry

Members involved

Main investigators

Pr Camiel BOON

Representative

Netherlands

Anterior Segment Rare Eye Diseases (WG4), Genetic Diagnostics (TWG6), National Integration (TWG9), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Others investigators

Pr Isabelle MEUNIER

Representative

France

Retinal Rare Eye Diseases (WG1)

Pr Bart LEROY

Representative

Belgium

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader